On Friday, Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS), surged 5.08% to $0.6410.
Aeterna Zentaris, declared that it has filed an application for a patent (European Patent Office priority application: EP15000132) on a novel method of manufacturing zoptarelin doxorubicin, its hybrid cytotoxic molecule that is the subject of a pivotal ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 clinical study in women with advanced, recurrent or metastatic endometrial cancer who have progressed and who have received one chemotherapeutic regimen with platinum and taxane (either as adjuvant or first-line treatment). The claimed manufacturing process is predictable to result in a noteworthy reduction in the cost of goods sold, providing a stronger competitive position for the Company.
Zoptarelin doxorubicin is a complex molecule that combines a synthetic peptide carrier with doxorubicin, a well-known chemotherapy agent. The synthetic peptide carrier is a Luteinizing Hormone Releasing Hormone agonist, a modified natural hormone with affinity for the LHRH receptor. The design of the compound allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH receptor-positive tumors. Potential benefits of this targeted approach comprise a better efficacy and a more favorable safety profile with lower incidence and severity of side effects as contrast to doxorubicin alone.
Because zoptarelin doxorubicin is a complex molecule, it is expensive to synthesize. The patent application, which is entitled “Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters”, may, if granted, make it difficult for generic manufacturers to produce the compound on a financially feasible basis after the Company’s composition‑of-matter patent on zoptarelin doxorubicin expires.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Shares of iGATE Corporation (NASDAQ:IGTE), gained 4.98% to $44.45, during its last trading session.
iGATE Corporation, has planned its Earnings Conference Call on Tuesday, May 5, 2015 to talk about the results of its first quarter ended March 31, 2015. Senior administration of the company will talk about the financial performance for the quarter and answer participants’ questions during the call.
The call will be webcast live on IGATE’s website (www.igate.com) in the Investor Relations page under the ‘Events’ section. Participants are requested to log in 10 minutes preceding to the start of the webcast. The on-demand version of the webcast will be accessible on the IGATE website shortly after the call.
iGATE Corporation, through its auxiliaries, provides information technology (IT) and IT-enabled operations offshore outsourcing solutions and services to large and medium-size organizations. It offers IT services, counting application development, application maintenance, business intelligence and analytics, cloud, business process outsourcing, engineering design, enterprise application solution, enterprise mobility, infrastructure administration, product and engineering solutions embedded systems, and product verification and validation services.
At the end of Friday’s trade, Shares of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM), gained 4.97% to $3.38.
Actinium Pharmaceuticals, declared that the first patient was successfully treated with Actimab-A drug candidate in the fourth and last cohort of the ongoing Phase 1/2 trial of Actimab-A. Actimab-A is being developed for newly diagnosed AML patients over the age of 60 ineligible for standard induction chemotherapy.
Patients in this last cohort are being treated at 2.0 μCi/kg per dose of Actimab-A. To date, three cohorts of patients have been treated at dose levels of 0.5, 1.0 and 1.5 μCi/kg per fractionated dose, respectively. The treatment comprises of two fractionated doses one week apart following cytoreduction with low dose cytarabine. Maximum tolerated dose (MTD) has not been reached yet and there was no peri-induction mortality among these high risk patients. However, dose dependent responses have been observed.
In the formerly accomplished third cohort in which patients received two doses of Actimab-A at 1.5 μCi/kg per dose, two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). “We are now moving towards completion of the Phase 1 portion of the trial,” said Dr. Kaushik Dave, the President and CEO of Actinium Pharmaceuticals. “The fact that at these late stages of the dose escalating trial we have confirmed an exemplary safety profile while already observing clinical responses and survival benefit is very encouraging.”
In this Phase 1/2 trial design, maximum tolerated dose will automatically become the Phase 2 portion dose.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies.
Finally, Rubicon Minerals Corporation (NYSEMKT:RBY), ended its last trade with 4.63% gain, and closed at $1.13.
Rubicon Minerals Corporation, declared that the development and construction of the Phoenix Gold Project in Red Lake, Ontario, Canada, is proceeding on plan and predictable to enter into initial production phase in mid-2015. The commissioning of the installation process began earlier than predictable and is predictable to continue throughout the second quarter of this year.
Rubicon presently has eight stepped various stages of development between the levels of 122 and 305 meters. The Company has a stock of about 11 600 tons of mineralized material. Storage then continue that development in the stands is growing and that operations stepped starts. A long-hole drilling trial is underway at the first step. Rubicon test different mining methods counting extraction steps using Alimak long holes. The Company plans to deal with the mineralized material continuously from mid-2015.
The Company is presently installing a crushing plant at the ore pass above the level of 305 meters. Crushed black soil will be transported to the level of 305 meters before the lifting process. A diagram of the crushing plant is shown in Figure 2. The remainder of the total capital allocated to underground development until the starting of the planned initial production of about 18 million CAD (March 31, 2015).
Rubicon Minerals Corporation engages in the acquisition, exploration, and development of gold properties in Canada and the United States. It primarily holds a 100% interest in Phoenix Gold project comprising of 16 patented mining claims, 25 licenses of occupation, 1 mineral lease, and 1 unpatented mining claim located in Bateman Township, Municipality of Red Lake, Ontario. The company was founded in 1996 and is headquartered in Toronto, Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
